GSK Buys Aiolos Bio for Up to $1.4 Bln
Updated Jan. 9, 2024 2:35 am ET
GSK said it bought biopharmaceutical company Aiolos Bio for an upfront consideration of $1.0 billion and the potential for an additional $400 million, the latest in a string of pharmaceutical majors buying fast-growing biotechs to restock their pipelines.
The British pharmaceutical giant said Tuesday that the deal to buy San Francisco and London-based Aiolos Bio, which focuses on patients with respiratory and inflammatory conditions, includes a Phase 2-ready antibody called AIO-001 for the treatment of adult patients with certain respiratory and inflammatory conditions.
Copyright ©2024 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Updated Jan. 9, 2024 2:35 am ET
GSK said it bought biopharmaceutical company Aiolos Bio for an upfront consideration of $1.0 billion and the potential for an additional $400 million, the latest in a string of pharmaceutical majors buying fast-growing biotechs to restock their pipelines.
The British pharmaceutical giant said Tuesday that the deal to buy San Francisco and London-based Aiolos Bio, which focuses on patients with respiratory and inflammatory conditions, includes a Phase 2-ready antibody called AIO-001 for the treatment of adult patients with certain respiratory and inflammatory conditions.
Copyright ©2024 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.